Vaxcyte's stock surges on promising vaccine data, offering potential upside despite competition. Learn more on PCVX here.

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

In the quest to add a digital readout to his mill, [Yuriy] has done a lot of homework. He’s sourced a trio of very capable scales, researched what kind of hardware his DRO should be based on ...

There's only one vaccine candidate for tick-borne infection Lyme disease in clinical development – Valneva and Pfizer's VLA15 – and it has just moved another step closer to being available.

There is a new pressure group in town. This particular benighted and besieged minority? Britain’s super rich, also known as ...

Despite the analysts’ downbeat assessment, Oliver Sartor, M.D., Director of Radiopharmaceutical Trials and Professor of ...

Shares in Insmed have rocketed after the biotech reported positive results in a highly-anticipated clinical trial of brensocatib in the respiratory disorder bronchiectasis. The phase 3 trial ...

The Focus Market Report provides weekly mean market expectations for inflation over following month, 12 months, and following year as well as expectations for Selic target rate, real GDP growth ...

JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics with an Overweight rating and a December 2025 price target of $80.

The White House has avoided Bangladesh issues in its readout, though the Indian side, through their Prime Minister’s Office, has said Biden and Modi discussed the situation in Bangladesh as well as ...

In addition, not all prices are measured in the monthly consumer price index, further complicating the readout. "We will look more at the granular data for price signals, rather than necessarily focus ...